MedPath

Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus

Not Applicable
Completed
Conditions
Diabetes
Interventions
Other: Meal replacement
Registration Number
NCT03155867
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

This will be a randomized, cross-over design. Subjects will be randomized to one of six interventions on six separate study days, 1 week apart.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Age 20-75 yrs
  • Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide (Glucotrol/Glucotrol XL) and glyburide (DiaBeta, Micronase, Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alpha-glucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset)
  • Hemoglobin A1C less than 9.0%
  • Fasting blood glucose less than 180 mg
  • Hematocrit levels within normal limits
Exclusion Criteria
  • Abnormal thyroid function
  • Creatinine >2.0 mg/dL
  • Potassium <3.5 mEq/L
  • Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting
  • Currently unstable diabetes or under treatment for cancer, heart disease, renal disease
  • Unable to give informed consent or follow instructions
  • Current insulin therapy or insulin therapy within the past month
  • Patient who are pregnant
  • Allergies to milk, soy or any component of the test product
  • Patient who in the Investigators assessment cannot be expected to comply with treatment
  • Currently participating or having participated in another clinical trial.
  • Patients with Anemia

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Meal replacement BMeal replacement-
Meal replacement EMeal replacement-
Meal replacement CMeal replacement-
Meal replacement DMeal replacement-
Meal replacement AMeal replacement-
Meal replacement FMeal replacement-
Primary Outcome Measures
NameTimeMethod
Area under the blood glucose curve (AUC 0-240)Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes
Secondary Outcome Measures
NameTimeMethod
Insulinogenic index [Change in Ins30/Change in Glu30]Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes
Area under the insulin curves (AUC 0-240)Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes
AUC (0-30min) for insulinBaseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes

Trial Locations

Locations (1)

Orange County Research Center

🇺🇸

Tustin, California, United States

© Copyright 2025. All Rights Reserved by MedPath